|
Volumn 43, Issue 3, 2011, Pages 901-904
|
Combined liver kidney transplantation: Critical analysis of a single-center experience
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BASILIXIMAB;
DACLIZUMAB;
METHYLPREDNISOLONE;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PEGINTERFERON;
PREDNISONE;
RIBAVIRIN;
TACROLIMUS;
ADULT;
AGED;
ALCOHOL LIVER CIRRHOSIS;
CLINICAL ARTICLE;
CONFERENCE PAPER;
CREATININE BLOOD LEVEL;
DIALYSIS;
EXPLANT;
GRAFT SURVIVAL;
HEPATITIS C;
HUMAN;
KIDNEY FAILURE;
KIDNEY GRAFT REJECTION;
KIDNEY POLYCYSTIC DISEASE;
KIDNEY TRANSPLANTATION;
LIVER ADENOMA;
LIVER CELL CARCINOMA;
LIVER FAILURE;
LIVER GRAFT;
LIVER GRAFT REJECTION;
LIVER ISCHEMIA;
LIVER KIDNEY TRANSPLANTATION;
LIVER TRANSPLANTATION;
MODEL FOR END STAGE LIVER DISEASE SCORE;
NONALCOHOLIC FATTY LIVER;
OUTCOME ASSESSMENT;
PATIENT SAFETY;
PRIMARY SCLEROSING CHOLANGITIS;
PRIORITY JOURNAL;
PROGNOSIS;
RECURRENT INFECTION;
SCORING SYSTEM;
SURGICAL TECHNIQUE;
SURVIVAL RATE;
ADOLESCENT;
ADULT;
AGED;
CONNECTICUT;
END STAGE LIVER DISEASE;
HUMANS;
KIDNEY TRANSPLANTATION;
LIVER TRANSPLANTATION;
MIDDLE AGED;
RENAL INSUFFICIENCY;
TREATMENT OUTCOME;
YOUNG ADULT;
|
EID: 79954476345
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/j.transproceed.2011.02.033 Document Type: Conference Paper |
Times cited : (10)
|
References (14)
|